ADITXT INC (ADTX) Stock News

NASDAQ:ADTX - Nasdaq - US0070258027 - Common Stock - Currency: USD

1.19 -0.07 (-5.56%)

After market: 1.2099 +0.02 (+1.67%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ADTX Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Aditxt, Inc.

Aditxt’s Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic® Ovarian Test

3 days ago - By: Benzinga - Mentions: CYH ABP APRE CASI ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

4 days ago - By: Aditxt, Inc.

Aditxt to Present at Wall Street Reporter’s Next Super Stock Livestream Today July 22, 2025, at 1 p.m. ET

11 days ago - By: Evofem Biosciences, Inc.

Phexxi -- A Non‑Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary Mommy

4 months ago - By: Benzinga

Why Aditxt (ADTX) Stock Is Skyrocketing

19 days ago - By: Aditxt, Inc.

Aditxt Unveils bitXbio™: A Bitcoin-Backed Treasury Strategy Designed to Accelerate Biotech Commercialization

a month ago - By: Aditxt, Inc.

Aditxt to Present at Wall Street Reporter’s NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET

2 months ago - By: Evofem Biosciences, Inc.

Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting

2 months ago - By: Aditxt, Inc.

Evofem Biosciences’ CEO Saundra Pelletier Joins Aditxt Board of Directors

2 months ago - By: Aditxt, Inc.

Saundra Pelletier, Evofem Biosciences’ CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6

2 months ago - By: Aditxt, Inc.

Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics

3 months ago - By: Aditxt, Inc.

Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™

3 months ago - By: Business Wire

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

3 months ago - By: Business Wire

KILL Dr. Charles Howe of the Mayo Clinic’s Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt’s Subsidiary Adimune™

3 months ago - By: Aditxt, Inc.

Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025

4 months ago - By: Aditxt, Inc.

Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements

4 months ago - By: Yahoo Finance - Mentions: TSLA

Why Aditxt Inc. (ADTX) Went Down On Thursday?

4 months ago - By: Aditxt, Inc.

Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements

4 months ago - By: Aditxt, Inc.

Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025

4 months ago - By: Aditxt, Inc.

Upcoming Aditxt Weekly Update to Highlight Pearsanta’s Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection

4 months ago - By: Evofem Biosciences, Inc. - Mentions: EVFM

Evofem Reports Fourth Consecutive Year of Net Sales Growth

4 months ago - By: Aditxt, Inc.

Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk